3-hexylcyclobutylcarboxylic acid | 88790-53-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-hexylcyclobutylcarboxylic acid
• 英文别名: 3-n-hexylcyclobutane-1-carboxylic acid；3-hexylcyclobutanecarboxylic acid；3-hexylcyclobutane-1-carboxylic acid
• CAS: 88790-53-8
• 化学式: C₁₁H₂₀O₂
• 分子量: 184.279
• InChiKey: RFGRFONKFRQOPL-UHFFFAOYSA-N

物化性质

• 熔点：
  47 °C(Solv: acetic acid (64-19-7))
• 沸点：
  283.9±8.0 °C(Predicted)
• 密度：
  0.986±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-hexylcyclobutylcarboxylic acid 在 吡啶 、 盐酸 、 氢氧化钾 、 lithium aluminium tetrahydride 、 三氯化铝 、 氯化亚砜 作用下， 以 乙醚 、 二甲基亚砜 为溶剂， 反应 45.5h， 生成
  参考文献：
  名称：

  Chan, L. K. M.; Gemmell, P. A.; Gray, G. W., Molecular Crystals and Liquid Crystals (1969-1991), 1989, vol. 168, p. 229 - 246

  摘要：

  DOI：
• 作为产物：
  描述：

  2-hexylpropane-1,3-diol di-p-toluenesulphonate 在 盐酸 、 氢氧化钾 、 sodium hydride 作用下， 以 1,4-二氧六环 为溶剂， 反应 11.5h， 生成 3-hexylcyclobutylcarboxylic acid
  参考文献：
  名称：

  Chain, L. K. M.; Gemmel, P. A.; Gray, G. W., Molecular Crystals and Liquid Crystals (1969-1991), 1987, vol. 147, p. 113 - 140

  摘要：

  DOI：

文献信息

• [EN] CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF<br/>[FR] ACIDES CARBOXYLIQUES CONTENANT UN CYCLOALKYLE ET LEURS UTILISATIONS
  申请人：LIMINAL BIOSCIENCES LTD

  公开号：WO2021124272A1

  公开（公告）日：2021-06-24

  The present application discloses a compound of formula (I) or a salt thereof: (I) and compositions comprising such compound or salt thereof. The use of such compound, salt thereof or composition comprising same for treating anemia or leukopenia, fibrosis, cancer, hypertension and/or a metabolic condition in a subject is also disclosed.

  本申请公开了化合物的结构式(I)或其盐：(I)，以及包含该化合物或其盐的组合物。还公开了利用该化合物、其盐或包含相同成分的组合物治疗受试者的贫血或白细胞减少症、纤维化、癌症、高血压和/或代谢状况的用途。
• As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
  申请人：——

  公开号：US20020013304A1

  公开（公告）日：2002-01-31

  A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves administration of a pharmaceutical formulation containing an effective amount of an androgenic agent, wherein administration is on an as-needed basis rather than involving chronic pharmacotherapy. Local delivery may be accomplished via administration to the vagina, vulvar area or urethra of the individual, although oral administration is preferred for those androgenic agents that are orally active. Formulations and kits for carrying out the method are provided as well.

  提供了一种提高女性性欲和性反应能力的方法。该方法包括给药含有有效量雄性激素的药物制剂，其中给药是按需给药，而不是长期药物治疗。局部给药可通过给药到个人的阴道、外阴部或尿道来实现，但对于那些口服活性的雄性激素制剂来说，口服给药是首选。此外，还提供了用于实施该方法的制剂和试剂盒。
• Treatment of dyspareunia with topically administered nitroglycerin formulations
  申请人：——

  公开号：US20040044080A1

  公开（公告）日：2004-03-04

  Methods and formulations for treating dyspareunia are provided. A pharmaceutical composition formulated so as to contain a therapeutically effective amount of nitroglycerin is administered to the vagina or vulvar area of the individual undergoing treatment. Preferred formulations are immediate release formulations in which at least 80% of the nitroglycerin in the formulation is released therefrom within 4 hours following administration. The formulations may contain one or more additional active agents, e.g., agents that are also useful to treat dyspareunia and/or potentiate the action of nitroglycerin. Such additional agents include vasoactive agents such as prostaglandins, phosphodiesterase inhibitors, androgens such as testosterone, estrogens such as estradiol, and selective modulators of estrogen and androgen receptors. A kit for a patient to use in the self-administration of the formulation is also provided.

  本研究提供了治疗性交困难的方法和制剂。将配制成含有治疗有效量硝化甘油的药物组合物施用到接受治疗者的阴道或外阴部位。首选的制剂是速释制剂，其中制剂中至少 80% 的硝酸甘油在给药后 4 小时内从制剂中释放出来。制剂可含有一种或多种额外的活性剂，例如，也可用于治疗性交困难和/或增强硝酸甘油作用的制剂。此类附加制剂包括血管活性剂，如前列腺素、磷酸二酯酶抑制剂、雄激素，如睾酮、雌激素，如雌二醇，以及雌激素和雄激素受体的选择性调节剂。此外，还提供了一种供患者用于自行服用制剂的试剂盒。
• As-needed administration of an androgenic agent to enhance female desire and responsiveness
  申请人：Wilson F. Leland

  公开号：US20050070516A1

  公开（公告）日：2005-03-31

  A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves administration of a pharmaceutical formulation containing an effective amount of an androgenic agent, wherein administration is on an as-needed basis rather than involving chronic pharmacotherapy. Local delivery may be accomplished via administration to the vagina, vulvar area or urethra of the individual, although oral administration is preferred for those androgenic agents that are orally active. Formulations and kits for carrying out the method are provided as well.

  提供了一种提高女性性欲和性反应能力的方法。该方法包括给药含有有效量雄性激素的药物制剂，其中给药是按需给药，而不是长期药物治疗。局部给药可通过给药到个人的阴道、外阴部或尿道来实现，但对于那些口服活性的雄性激素制剂来说，口服给药是首选。此外，还提供了用于实施该方法的制剂和试剂盒。
• Pharmaceutical compositions for the treatment of sexual disorders II
  申请人：Mendla Klaus

  公开号：US20050245539A1

  公开（公告）日：2005-11-03

  The invention relates to new pharmaceutical compositions for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment of sexual disorders and methods for the preparation thereof.

  本发明涉及用于治疗性障碍的新型药物组合物及其制备方法。在一个优选的实施方案中，本发明涉及由氟班色林作为一种活性成分与至少一种额外的活性成分组合而成的用于治疗性障碍的药物组合物及其制备方法。